COMPANY PROFILE
NeoCardium Limited is a company incorporated in United Kingdom with a focus in developing and assisting development of a new category of cardiology devices. The clinical indications for company’s proprietary device technology include applications in the practice of interventional cardiology and the new branch of Regenerative Cardiology.

While Company’s expertise in Regenerative Cardiology is currently offered as consulting or collaborative services to companies engaged in gene or stem cell based heart repair business, NeoCardium’s in-house product development is currently planned for a huge unmet need in the practice of interventional cardiology. Globally about 7 million angioplasties are performed every year. Each one of the 7 million angioplasty patients may run a 30 percent to 40 percent risk of restenosis. Stents were originally developed to address the restenosis problem, but in-stent restonsis still remains a significant problem. With Company’s product priced at a modest $300 for 6 month treatment, the global annual potential addressable market for post-angioplasty (in-stent) restenosis prevention market exceeds < $2.1 billion. The clinical indication for which Company is getting ready for clinical trials is:

“Prevention of post procedure coronary restenosis in patients undergoing uncomplicated elective percutaneous transluminal coronary angioplasty.”

Since the device is a Class IIa under European Classification of devices the cost and time to market for this indication will be significantly low. There are other clinical indications that Company’s technology platform can be deployed. The Company is currently soliciting investors / partners for developing Company’s flagship indication for preventing post-angioplasty in-stent restenosis.